This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Beijing Institute for Cancer Research. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Baocai Xing: Innovator in Cancer Research
Introduction
Baocai Xing is a prominent inventor based in Beijing, China. He has made significant contributions to the field of cancer research, particularly in the identification and treatment of tumor-initiating cells. His innovative work has led to the development of a valuable patent that addresses critical challenges in oncology.
Latest Patents
Baocai Xing holds a patent titled "Antibody and binding fragment recognizing CACNA2D1 and use thereof." This patent discloses a method for searching, identifying, or validating a marker CACNA2D1 of tumor-initiating cells. The method involves immunizing an animal using HEP-12 cells originating from a recurrent tumor that is rich in originating cells. Additionally, the patent describes a monoclonal antibody that specifically recognizes CACNA2D1 or antigen-binding fragments thereof. This innovation has potential applications for treating or preventing tumors or diseases related to CACNA2D1. Baocai Xing has 1 patent to his name.
Career Highlights
Baocai Xing is affiliated with the Beijing Institute for Cancer Research, where he conducts his research and development activities. His work is instrumental in advancing the understanding of cancer biology and improving therapeutic strategies.
Collaborations
Baocai Xing collaborates with notable colleagues, including Zhiqian Zhang and Wei Zhao. Their combined expertise enhances the research efforts at the Beijing Institute for Cancer Research.
Conclusion
Baocai Xing's contributions to cancer research through his innovative patent demonstrate his commitment to advancing medical science. His work has the potential to significantly impact the treatment of cancer and improve patient outcomes.